Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates

NCT00961753 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped FDA drug recall on July 30, 2010

Conditions

Patent Ductus Arteriosus

Interventions

DRUG: optimized ibuprofen
DRUG: Standard Ibuprofen

Sponsor

OSF Healthcare System